(NASDAQ: ARVN) Arvinas's forecast annual revenue growth rate of -19.88% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.66%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.06%.
Arvinas's revenue in 2026 is $262,600,000.On average, 20 Wall Street analysts forecast ARVN's revenue for 2026 to be $5,818,659,819, with the lowest ARVN revenue forecast at $1,040,517,499, and the highest ARVN revenue forecast at $11,537,924,249. On average, 18 Wall Street analysts forecast ARVN's revenue for 2027 to be $4,658,471,295, with the lowest ARVN revenue forecast at $1,943,135,089, and the highest ARVN revenue forecast at $10,000,301,881.
In 2028, ARVN is forecast to generate $10,091,126,497 in revenue, with the lowest revenue forecast at $1,942,623,401 and the highest revenue forecast at $35,312,226,834.